-
GlaxoSmithKline's Immunotherapy For Endometrial Cancer Wins FDA Approval
2021 Apr 22, 2:13pm | 222Read More...The FDA has granted accelerated approval to GlaxoSmithKline plc's (NYSE: GSK) Jemperli (dostarlimab) for endometrial cancer. The approval covers patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with platinum-...
-
Moderna's Flagship Venture Firm Cashed $1.4B From Stock Sale In Two Months: Forbes
2021 Apr 22, 1:53pm | 354Read More...Almost a decade ago, Flagship Pioneering, a VC fund run and majority-owned by Moderna Inc’s (NASDAQ: MRNA) chairman and co-founder, Noubar Afeyan, poured cash into the company, even when Moderna had faced some early setbacks. Over the last 13 months, since the World Health...
-
Zogenix's Fintepla Associated With Improvements in Seizure Control, Executive Functions In Childhood Epilepsy Disorder
2021 Apr 22, 10:51am | 284Read More...Zogenix Inc (NASDAQ: ZGNX) has announced new data showing the positive impact of treatment with Fintepla (fenfluramine) on everyday executive function for children and young adults with Lennox-Gastaut syndrome (LGS), a rare and severe kind of childhood epilepsy characterized by...
-
Biogen's Shares Are Trading Lower On 71% Quarterly Profit Slump, Weak Tecfidera Sales
2021 Apr 22, 10:50am | 303Read More...Biogen Inc (NASDAQ: BIIB) reported a 70.7% fall in Q1 profit as its top-selling multiple sclerosis drug Tecfidera faced increased competition from cheaper generic drugs. Net income fell to $410.2 million, or $2.69 per share for the quarter from $1.40 billion, or $8.08 per share...
-
Vertex Pharma Inks Research, Licensing Agreement With Obsidian Therapeutics For Controllable Genetic Therapies
2021 Apr 22, 9:06am | 207Read More...Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Privately-held Obsidian Therapeutics have entered into a research collaboration and licensing agreement to discover novel therapies that regulate gene editing. The collaboration leverages Obsidian's cytoDRiVE platform...
-
Aptorum Shares Are Trading Higher On Immunomodulators Agreement For Autoimmune, Oncology Indications
2021 Apr 22, 9:04am | 195Read More...Aptorum Group Ltd (NASDAQ: APM) has entered into a material transfer and option agreement with Yale University to evaluate a group of preclinical stage novel immunomodulators. Aptorum also obtained an exclusive option to in-license the novel immunomodulators and related...
-
The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs
2021 Apr 22, 8:08am | 2141Read More...Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) Axonics, Inc. (NASDAQ: AXNX) BioNTech SE (NASDAQ: BNTX) Bio-Techne Corporation (NASDAQ: TECH) Boston...
-
Can-Fite Expands Mid-Stage COVID-19 Study To Europe
2021 Apr 22, 8:07am | 233Read More...Can-Fite BioPharma Ltd (NYSE: CANF) has expanded its Phase 2 COVID-19 study of Piclidenoson to two European countries, Romania and Bulgaria. The randomized, double-blind, placebo-controlled study evaluates Piclidenoson plus standard supportive care (SSC) vs. placebo plus SSC in...
-
Bristol Myers To Build First Cell Therapy Factory In Europe
2021 Apr 22, 8:02am | 282Read More...Bristol-Myers Squibb Co (NYSE: BMY) continues to scale its CAR-T operations with the latest move to open its first cell manufacturing site in Europe and fifth worldwide. BMY is set to build a new cell therapy site in Leiden, the Netherlands. Financial terms were not disclosed....
-
Renalytix AI Stock Jumps After 10-Year US Government Contract For Kidney Disease Testing Services
2021 Apr 22, 7:58am | 188Read More...Renalytix AI plc (NASDAQ: RNLX) stock is rising on the heels of a 10-year contract from the United States Government to provide KidneyIntelX early-stage kidney disease bioprognostic testing services. The contract, offered through the General Services Administration, covers...
-
AstraZeneca's MEDI5884-PCSK9 Inhibitor Combo Shows Promise In Heart Disease
2021 Apr 22, 6:56am | 365Read More...Most heart disease drugs are aimed at reducing the "bad" low-density lipoprotein (LDL) cholesterol. However, strategies related to cutting LDL cholesterol and increasing high-density lipoprotein (HDL) cholesterol are of interest in combating the risk of heart disease. HDL cholesterol is...
-
AstraZeneca Can Face Legal Action Over Vaccine Shortfalls To EU: Reuters
2021 Apr 22, 6:07am | 486Read More...The European Commission is reportedly working on legal proceedings against AstraZeneca Plc (NASDAQ: AZN) as the company cut COVID-19 vaccine deliveries to the European Union. The move comes as one step further as an E.U. plan to break off ties with AstraZeneca after...
-
Pfizer Sounds Alarm Against Counterfeit COVID-19 Vaccines: What You Need To Know
2021 Apr 22, 2:42am | 468Read More...Pfizer Inc (NYSE: PFE) has come to know of counterfeit versions of its COVID-19 vaccine in Poland and Mexico, the Wall Street Journal reported Wednesday. What Happened: The New York-based pharmaceutical giant tested vials recovered by authorities in both countries and confirmed they contained...
-
2 Biopharma Stocks That Look Ready For A Bullish Reversal
2021 Apr 21, 3:27pm | 458Read More...Ocugen Inc. (NASDAQ: OCGN) and Bionano Inc. (NASDAQ: BNGO) are two biopharma stocks moving higher Wednesday. Ocugen is moving after its partner Bharat Biotech announced positive study results, and Bionano gained ground after its system for optical genome mapping was adopted by two large...
-
Novo Nordisk To Start Phase 3 Obesity Trial With Oral Semaglutide
2021 Apr 21, 1:53pm | 236Read More...Novo Nordisk A/S (NYSE: NVO) is entering the Phase 3a study in obesity with oral semaglutide 50 mg. The decision follows the completion of the STEP phase 3a trial with once-weekly subcutaneously administered semaglutide 2.4 mg. The company will launch the trial in the second...
